Celcuity

$CELC will report on Q4 and full year 2025 financial results next Wednesday, March 25, 2026. Celcuity management will host a webcast conference call at 4:30 pm ET. Learn more: bit.ly/4uTNu87

Results from the Phase 3 VIKTORIA-1 trial were published in @JCO_ASCO. We would like to thank Dr. Sara Hurvitz for serving as a co-primary investigator and for helping us potentially bring this important therapy to patients. Read the manuscript: bit.ly/4uCIx3p

We are proud to announce publication in the Journal of Clinical Oncology of results from the Phase 3 VIKTORIA-1 clinical trial. Read more here: bit.ly/4ujOzWn $CELC #gedatolisib

Tune in tomorrow to listen to our fireside chat at the Leerink Global Healthcare Conference: bit.ly/4c6WAqY $CELC

Tune in tomorrow to listen to our fireside chat at the TD Cowen 46th Annual Health Care Conference: bit.ly/4qOFgKZ

We look forward to attending the upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference, Leerink Global Healthcare Conference, and the 2026 Jefferies Biotech on the Beach Summit. For more information: bit.ly/4cf7mvs $CELC

We are pleased to announce the appointment of Chip Romp to Celcuity’s Board of Directors. Mr. Romp brings over 25 years of experience in the pharmaceutical industry to $CELC, with an emphasis on leading commercial organizations in the oncology setting. bit.ly/4rSQPlw

Tune in tomorrow and listen to our fireside chat with Celcuity CEO, Brian Sullivan, and biotech research analyst, Brad Canino, at the Guggenheim Emerging Outlook: Biotech Summit 2026. Listen to the webcast: bit.ly/3NRO2dr

$CELC is participating in a fireside chat and hosting investor meetings at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. Read more here: bit.ly/45QFxFM

$CELC is proud to announce the acceptance of our NDA for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer. Read more here: bit.ly/4sQ5sqI

#News: Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer PR Here: ir.celcuity.com/press-releases/ #teamcelcuity #oncology #biotechnology

Yesterday, Dr. Barbara Pistilli presented additional subgroup analysis and safety data from the Phase 3 VIKTORIA-1 trial. View the presentation here: bit.ly/48LO6lM

At this year’s SABCS meeting, we will share new data for gedatolisib from the Phase 3 VICKTORIA -1 trial in patients with HR+/HER2-/PIK3CA-wild type advanced breast cancer in a rapid oral session. Read our press release: bit.ly/4pEJkOm

#News: Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium PR Here: ir.celcuity.com/press-releases/ #teamcelcuity #oncology #biotechnology

#News: Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium PR Here: ir.celcuity.com/press-releases/ #teamcelcuity #oncology #biotechnology

#News: Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference PR Here: ir.celcuity.com/press-releases/ #teamcelcuity #oncology #biotechnology

#News: Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer PR Here: ir.celcuity.com/press-releases/ #teamcelcuity #oncology #biotechnology

#NEWS: Celcuity Reports Third Quarter 2025 Financial Results and Provides Corporate Update: ir.celcuity.com/press-releases/ A live webcast/conference call at 4:30 p.m. ET today can be accessed using this weblink: viavid.webcasts.com/starthere.jsp?… #teamcelcuity #earnings #oncology

#NEWS: Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial Press release here: ir.celcuity.com/press-releases/ #teamcelcuity #breastcancer #data

#NEWS: Celcuity presents updated data at the 2025 ESMO congress from Phase 1 study evaluating gedatolisib plus darolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”) Press Release here: ir.celcuity.com/press-releases/ #teamcelcuity #prostatecancer #ESMO